1. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer‐BioNTech COVID‐19 vaccine—United States, December 2020;Oliver SE;MMWR Morb Mortal Wkly Rep,2020
2. The Advisory Committee on Immunization Practices’ interim recommendation for allocating initial supplies of COVID‐19 vaccine—United States, 2020;Dooling K;MMWR Morb Mortal Wkly Rep,2020
3. Vaccine‐associated hypersensitivity;McNeil MM;J Allergy Clin Immunol,2018
4. CDC.COVID‐19 vaccination: clinical considerations. Interim clinical considerations for use of mRNA COVID‐19 vaccines currently authorized in the United States.Atlanta GA:US Department of Health and Human Services CDC;2020.https://www.cdc.gov/vaccines/covid‐19/info‐by‐product/clinical‐considerations.html.
5. CDC.COVID‐19 vaccination: clinical considerations. Interim considerations: preparing for the potential management of anaphylaxis after COVID‐19 vaccination.Atlanta GA:US Department of Health and Human Services CDC;2020.https://www.cdc.gov/vaccines/covid‐19/info‐by‐product/pfizer/anaphylaxis‐management.html.